drugset / Trial / NCT04567290

Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome

NCT04567290 ↗

Phase 4 Unknown 50 enrolled Centro Hospitalario La Concepcion
RandomizedParallel-groupOpen-labelTreatment

Summary

The study aims to determine the pharmacodynamic performance in the first hour measured with verifynow, of the conventional ticagrelor loaded dose versus chewed ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention

Timeline

Start
2020-10-07
Primary completion
2021-08-15
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 180 mg Oral